Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Varenicline Treatment for Smoking Cessation in Patients With Bipolar Disorder
Brief Summary: The investigators' hypothesis is that add-on varenicline will be effective (versus placebo) in initiating abstinence from smoking in subjects with stable, euthymic bipolar disorder who are motivated to quit smoking within four weeks. This primary outcome will be assessed from randomization to 12 weeks or end of the treatment phase of the study. Secondarily, the investigators also hypothesize that varenicline will prevent relapse in the subsequent 12-weeks follow-up non-treatment phase. Furthermore, the investigators plan to test the effectiveness of varenicline in reducing nicotine withdrawal symptoms or urges to smoke, as well as its safety for use in stable bipolar patients when used as an add-on treatment for smoking cessation.

The investigators plan to test these hypotheses by conducting a randomized, placebo-controlled add-on treatment trial of Chantix with 60 recruited subjects diagnosed with DSM-IV bipolar disorder for a period of three months. The investigators will follow-up with them three months later to evaluate extended abstinence.


Options:
A: Arm Label: Gain Framed Absitnence Program; Type: ACTIVE_COMPARATOR; Interventions: Drug: Bupropion, Behavioral: Smoking Abstinence Program | Arm Label: Loss Framed Abstinence Program; Type: ACTIVE_COMPARATOR; Interventions: Drug: Bupropion, Behavioral: Smoking Abstinence Program | Intervention Type: DRUG; Name: Bupropion; Assigned to Arm(s): Gain Framed Absitnence Program, Loss Framed Abstinence Program | Intervention Type: BEHAVIORAL; Name: Smoking Abstinence Program; Assigned to Arm(s): Gain Framed Absitnence Program, Loss Framed Abstinence Program
B: Arm Label: Bupropion; Type: EXPERIMENTAL; Interventions: Drug: Bupropion, Behavioral: Smoking Cessation Counseling | Arm Label: Varenicline; Type: EXPERIMENTAL; Interventions: Drug: Varenicline, Behavioral: Smoking Cessation Counseling | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Behavioral: Smoking Cessation Counseling | Intervention Type: DRUG; Name: Bupropion; Assigned to Arm(s): Bupropion | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Varenicline | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: BEHAVIORAL; Name: Smoking Cessation Counseling; Assigned to Arm(s): Bupropion, Placebo, Varenicline
C: Arm Label: Varenicline; Type: EXPERIMENTAL; Interventions: Drug: Varenicline | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Varenicline | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Order 1; Type: EXPERIMENTAL; Interventions: Drug: Nicotine Nasal Spray, Drug: Varenicline, Drug: Placebo Nasal Spray, Drug: Placebo Varenicline | Arm Label: Order 2; Type: EXPERIMENTAL; Interventions: Drug: Nicotine Nasal Spray, Drug: Varenicline, Drug: Placebo Nasal Spray, Drug: Placebo Varenicline | Arm Label: Order 3; Type: EXPERIMENTAL; Interventions: Drug: Nicotine Nasal Spray, Drug: Varenicline, Drug: Placebo Nasal Spray, Drug: Placebo Varenicline | Arm Label: Order 4; Type: EXPERIMENTAL; Interventions: Drug: Nicotine Nasal Spray, Drug: Varenicline, Drug: Placebo Nasal Spray, Drug: Placebo Varenicline | Intervention Type: DRUG; Name: Nicotine Nasal Spray; Assigned to Arm(s): Order 1, Order 2, Order 3, Order 4 | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Order 1, Order 2, Order 3, Order 4 | Intervention Type: DRUG; Name: Placebo Nasal Spray; Assigned to Arm(s): Order 1, Order 2, Order 3, Order 4 | Intervention Type: DRUG; Name: Placebo Varenicline; Assigned to Arm(s): Order 1, Order 2, Order 3, Order 4

Answer: C